Published in N Engl J Med on March 30, 2006
Multiple myeloma. Blood (2008) 5.88
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
A monoclonal gammopathy precedes multiple myeloma in most patients. Blood (2009) 3.98
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat Biotechnol (2014) 2.54
B-cell responses to vaccination at the extremes of age. Nat Rev Immunol (2009) 2.50
Treatment of multiple myeloma. Nat Rev Clin Oncol (2011) 2.46
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood (2015) 2.46
IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol (2010) 2.35
Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest (2012) 2.24
Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park) (2011) 2.21
B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell (2008) 2.15
Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol (2007) 2.14
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Screening panels for detection of monoclonal gammopathies. Clin Chem (2009) 2.05
The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood (2008) 2.05
Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals. Clin Infect Dis (2012) 2.01
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood (2010) 1.98
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood (2009) 1.90
Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc (2009) 1.88
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood (2008) 1.78
Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol (2007) 1.74
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med (2007) 1.73
Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood (2013) 1.64
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A (2008) 1.59
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia (2013) 1.54
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol (2010) 1.42
Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood (2006) 1.39
Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol (2010) 1.36
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol (2012) 1.35
Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol (2011) 1.31
Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood (2009) 1.30
Morbidity and mortality among older individuals with undiagnosed celiac disease. Gastroenterology (2010) 1.29
Al amyloidosis. Orphanet J Rare Dis (2012) 1.29
Kidney disease and multiple myeloma. Clin J Am Soc Nephrol (2013) 1.26
C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis (2013) 1.24
Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc (2013) 1.20
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica (2009) 1.19
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood (2009) 1.15
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood (2010) 1.13
Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility. Sci Transl Med (2015) 1.12
Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc (2010) 1.11
New advances in renal amyloidosis. Clin Exp Nephrol (2008) 1.10
MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct (2011) 1.10
Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc (2010) 1.09
Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc (2012) 1.09
Ageing is associated with diminished apoptotic cell clearance in vivo. Clin Exp Immunol (2008) 1.09
Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol (2010) 1.08
Management of paraproteinaemia. Postgrad Med J (2007) 1.08
Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res (2009) 1.08
Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc (2016) 1.07
Inherited neuropathies: clinical overview and update. Muscle Nerve (2013) 1.05
Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol (2011) 1.04
Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol (2013) 1.04
Multiple myeloma. Curr Probl Cancer (2009) 1.04
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
Smoldering multiple myeloma. Blood (2015) 1.03
Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia (2011) 1.03
Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol (2011) 1.01
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood (2009) 1.00
Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients. Leukemia (2013) 1.00
Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol (2008) 1.00
Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program (2011) 1.00
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia (2012) 0.99
Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol (2009) 0.98
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood (2012) 0.96
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res (2012) 0.96
Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc (2010) 0.95
Kidney disease associated with plasma cell dyscrasias. Blood (2010) 0.95
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2016) 0.94
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica (2011) 0.94
Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB. Oncotarget (2014) 0.93
Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma (2013) 0.93
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood (2011) 0.93
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun (2015) 0.92
Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin Lymphoma Myeloma Leuk (2014) 0.91
Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia. Clin Lymphoma Myeloma (2009) 0.91
Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc (2012) 0.90
MicroRNA: important player in the pathobiology of multiple myeloma. Biomed Res Int (2014) 0.89
Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms. Biomark Res (2013) 0.89
The significance of monoclonal gammopathy of undetermined significance. Haematologica (2009) 0.88
Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing. Oncotarget (2012) 0.88
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica (2014) 0.88
Familial multiple myeloma: report on two families and discussion of screening options. Hered Cancer Clin Pract (2007) 0.88
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia (2014) 0.88
Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev (2009) 0.87
Effects of aging on the adaptive immune response to respiratory virus infections. Aging health (2009) 0.86
Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation (2013) 0.86
DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle (2013) 0.86
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood (2011) 0.86
Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol (2014) 0.86
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Epidemiology and outcomes of osteoporotic fractures. Lancet (2002) 13.09
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Multiple myeloma. N Engl J Med (2004) 10.81
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol (2011) 8.00
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc (2012) 6.54
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc (2012) 6.21
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med (2005) 5.94
Multiple myeloma. Blood (2008) 5.88
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
Meckel diverticulum: the Mayo Clinic experience with 1476 patients (1950-2002). Ann Surg (2005) 4.72
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol (2012) 4.47
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med (2002) 4.18
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum (2010) 3.84
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol (2006) 3.81
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
A reference standard for the description of osteoporosis. Bone (2007) 3.67
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol (2009) 3.42
Natural history of asymptomatic mitral valve prolapse in the community. Circulation (2002) 3.40
Why patients visit their doctors: assessing the most prevalent conditions in a defined American population. Mayo Clin Proc (2013) 3.40
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Significant reduction in risk of falls and back pain in osteoporotic-kyphotic women through a Spinal Proprioceptive Extension Exercise Dynamic (SPEED) program. Mayo Clin Proc (2005) 3.26
Trends in the mortality burden associated with diabetes mellitus: a population-based study in Rochester, Minn, 1970-1994. Arch Intern Med (2003) 3.13
Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol (2004) 3.11
Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res (2005) 3.11
Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc (2002) 3.09
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging (2010) 3.03
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87